Tags

Type your tag names separated by a space and hit enter

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Neurology. 2011 Feb 22; 76(8 Suppl 3):S20-7.Neur

Abstract

The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high affinity to 4 of the 5 G-protein-coupled S1P receptors (S1P(1-5)). After binding, the receptors are internalized, degraded, and thus functionally antagonized by fingolimod. Under physiologic conditions, S1P(1) mediates the egress of lymphocytes from secondary lymphoid organs to the peripheral circulation. Functional antagonism of S1P(1) by fingolimod results in a reduction in peripheral lymphocyte counts by inhibiting egress of lymphocytes, including potentially encephalitogenic T cells and their naïve progenitors that would otherwise be present within the circulation. Despite the fingolimod-mediated reduction of lymphocyte counts, fingolimod-treated patients with MS have been shown to have few infections and related complications and were able to mount antigen-specific immune responses in vaccination studies.

Authors+Show Affiliations

Department of Neurology, University Hospital, Basel, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21339487

Citation

Mehling, M, et al. "Clinical Immunology of the Sphingosine 1-phosphate Receptor Modulator Fingolimod (FTY720) in Multiple Sclerosis." Neurology, vol. 76, no. 8 Suppl 3, 2011, pp. S20-7.
Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011;76(8 Suppl 3):S20-7.
Mehling, M., Johnson, T. A., Antel, J., Kappos, L., & Bar-Or, A. (2011). Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology, 76(8 Suppl 3), S20-7. https://doi.org/10.1212/WNL.0b013e31820db341
Mehling M, et al. Clinical Immunology of the Sphingosine 1-phosphate Receptor Modulator Fingolimod (FTY720) in Multiple Sclerosis. Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. PubMed PMID: 21339487.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. AU - Mehling,M, AU - Johnson,T A, AU - Antel,J, AU - Kappos,L, AU - Bar-Or,A, PY - 2011/2/23/entrez PY - 2011/2/26/pubmed PY - 2011/3/12/medline SP - S20 EP - 7 JF - Neurology JO - Neurology VL - 76 IS - 8 Suppl 3 N2 - The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high affinity to 4 of the 5 G-protein-coupled S1P receptors (S1P(1-5)). After binding, the receptors are internalized, degraded, and thus functionally antagonized by fingolimod. Under physiologic conditions, S1P(1) mediates the egress of lymphocytes from secondary lymphoid organs to the peripheral circulation. Functional antagonism of S1P(1) by fingolimod results in a reduction in peripheral lymphocyte counts by inhibiting egress of lymphocytes, including potentially encephalitogenic T cells and their naïve progenitors that would otherwise be present within the circulation. Despite the fingolimod-mediated reduction of lymphocyte counts, fingolimod-treated patients with MS have been shown to have few infections and related complications and were able to mount antigen-specific immune responses in vaccination studies. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/21339487/Clinical_immunology_of_the_sphingosine_1_phosphate_receptor_modulator_fingolimod__FTY720__in_multiple_sclerosis_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=21339487 DB - PRIME DP - Unbound Medicine ER -